ViewRay, which markets the first and only FDA-approved MRI-guided radiation therapy system, withdrew its plans for an initial public offering on Thursday.
The company had planned to raise $52 million at a fully diluted market cap of $204 million by listing ...read more
ViewRay, which markets the only MRI radiation therapy system that images and treats patients simultaneously, announced terms for its IPO on Friday. The Oakwood Village, OH-based company plans to raise $52 million by offering 4 million shares at a price range of ...read more
Mevion Medical Systems, which markets recently-approved proton radiation therapy systems to treat cancer, filed on Thursday with the SEC to raise up to $69 million in an initial public offering. The company first received 510(k) clearance from the FDA in July...read more
Accuray, which offers an FDA-approved robotic radiosurgery system to treat solid tumors, priced its IPO of 16 million shares at $18, a 20% premium to the midpoint of its originally proposed $14 to $16 range, on Wednesday night. The pricing came in at the high...read more
ViewRay no longer focused on IPO: MRI maker withdraws plans to go public
ViewRay, which markets the first and only FDA-approved MRI-guided radiation therapy system, withdrew its plans for an initial public offering on Thursday. The company had planned to raise $52 million at a fully diluted market cap of $204 million by listing ...read more
See cancer, treat cancer: ViewRay sets terms for $52 million IPO
ViewRay, which markets the only MRI radiation therapy system that images and treats patients simultaneously, announced terms for its IPO on Friday. The Oakwood Village, OH-based company plans to raise $52 million by offering 4 million shares at a price range of ...read more
Cancer-fighting device company Mevion Medical files for a $69 million IPO
Mevion Medical Systems, which markets recently-approved proton radiation therapy systems to treat cancer, filed on Thursday with the SEC to raise up to $69 million in an initial public offering. The company first received 510(k) clearance from the FDA in July...read more
Medical device firm Accuray prices atop revised range
Accuray, which offers an FDA-approved robotic radiosurgery system to treat solid tumors, priced its IPO of 16 million shares at $18, a 20% premium to the midpoint of its originally proposed $14 to $16 range, on Wednesday night. The pricing came in at the high...read more